| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... The Lancet 397 (10274), 592-604, 2021 | 620 | 2021 |
| Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus HM Turk, A Sevinc, C Camci, A Cigli, S Buyukberber, H Savli, N Bayraktar Acta diabetologica 39, 117-122, 2002 | 179 | 2002 |
| Zolbetuximab plus CAPOX in CLDN18. 2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial MA Shah, K Shitara, JA Ajani, YJ Bang, P Enzinger, D Ilson, F Lordick, ... Nature medicine 29 (8), 2133-2141, 2023 | 136 | 2023 |
| How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma A Sevinc, C Camci, HM Turk, S Buyukberber Oncology 65 (1), 1-6, 2003 | 118 | 2003 |
| Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study ZA Wainberg, PC Enzinger, YK Kang, S Qin, K Yamaguchi, IH Kim, ... The Lancet Oncology 23 (11), 1430-1440, 2022 | 115 | 2022 |
| The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus G Ak, S Buyukberber, A Sevinc, HM Turk, M Ates, R Sari, H Savli, A Cigli Journal of Diabetes and its Complications 15 (3), 150-157, 2001 | 113 | 2001 |
| Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid HM Turk, H Pekdemir, S Buyukberber, A Sevinc, C Camci, R Kocabas, ... Tumor biology 24 (4), 172-175, 2003 | 102 | 2003 |
| Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids A Sevinc, S Buyukberber, R Sari, Y Kiroglu, HM Turk, M Ates Gynecologic oncology 77 (2), 254-257, 2000 | 96 | 2000 |
| Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric … ZA Wainberg, PC Enzinger, YK Kang, K Yamaguchi, S Qin, KW Lee, ... Journal of Clinical Oncology 39 (3_suppl), 160-160, 2021 | 82 | 2021 |
| Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. A Sevinc, S Buyukberber, R Sari, HM Turk, M Ates Anticancer Research 20 (2B), 1201-1203, 2000 | 46 | 2000 |
| LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... Annals of Oncology 31, S1182-S1183, 2020 | 39 | 2020 |
| Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study AI Yasin, SG Aydin, B Sümbül, L Koral, M Şimşek, Ç Geredeli, A Öztürk, ... Future Oncology 18 (10), 1235-1244, 2022 | 36 | 2022 |
| FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal … DVT Catenacci, YK Kang, A Saeed, K Yamaguchi, S Qin, KW Lee, IH Kim, ... Journal of Clinical Oncology 39 (15_suppl), 4010-4010, 2021 | 36 | 2021 |
| Colon carcinoma with synchronous subcutaneous and osseous metastasis: a case report C Camci, HM Türk, S Büyükberber, M Karakök, M Koruk, Y Beyazity, ... The Journal of Dermatology 29 (6), 362-365, 2002 | 32 | 2002 |
| Relationship between plasma adrenomedullin levels and metabolic control, risk factors, and diabetic microangiopathy in patients with type 2 diabetes. HM Turk, S Buyukberber, A Sevinc, G Ak, M Ates, R Sari, H Savli, A Cigli Diabetes Care 23 (6), 864-867, 2000 | 30 | 2000 |
| Zolbetuximab+ CAPOX in 1L claudin-18.2+(CLDN18. 2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 … R Xu, K Shitara, JA Ajani, YJ Bang, PC Enzinger, DH Ilson, F Lordick, ... Journal of Clinical Oncology 41 (36_suppl), 405736-405736, 2023 | 29 | 2023 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial AO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ... Annals of Oncology 35 (1), 107-117, 2024 | 28 | 2024 |
| Paraneoplastic motor neuron disease resembling amyotrophic lateral sclerosis in a patient with renal cell carcinoma HM Turk, A Ozet, O Kuzhan, F Komurcu, F Arpaci, B Ozturk, S Ataergin Medical Principles and Practice 18 (1), 73-75, 2008 | 28 | 2008 |
| Granulocytic sarcoma of the colon and leukemic infiltration of the liver in a patient presenting with hematochezia and jaundice A Sevinc, S Buyukberber, C Camci, M Koruk, MC Savas, HM Turk, I Sari, ... Digestion 69 (4), 262-265, 2004 | 22 | 2004 |
| Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer ME Kalender, A Sevinc, C Camci, HM Turk, M Karakok, B Akgul Oncology 73 (5-6), 415-418, 2008 | 20 | 2008 |
